Neeraj Agarwal, MD, a clinician and researcher at the University of Utah Huntsman Cancer Institute, discusses investigational combinations with PARP inhibitors in prostate cancer treatment.
Neeraj Agarwal, MD, a clinician and researcher at the University of Utah Huntsman Cancer Institute, discusses promising investigational combinations including PARP inhibitors in the treatment of prostate cancer.
PARP inhibitors are being studied in combination with other therapies—which regimens being studied do you believe hold the most promise in prostate cancer?
I think the combination of PARP inhibitors with novel hormonal therapy definitely has promise. So whether it’s a combination of talazoparib with enzalutamide as being tested in TALAPRO-2 trial, or niraparib with abiraterone in the MAGNITUDE trial, and then olaparib with abiraterone in the PROPEL trial, I think all of these combinations have promise. Also the AMPLITUDE trial as I said early on, for patients with metastatic castration-sensitive prostate cancer, is a combination of abiraterone with niraparib that has promise, too. So I think that as a class, PARP inhibitors with novel hormonal therapy have a lot of scientific rationale. There is another clinical trial going on, the KEYLYNK trial, where olaparib is being tested in combination with pembrolizumab, which is an immune checkpoint inhibitor, in late metastatic castrate-resistant prostate cancer. I think that combination is also promising. Ultimately, the data will tell us whether these combinations are going to be approved or not, within next 1, 2, or 3 years. So we're really looking forward to the results of those trials.